Evaxion Biotech AS ADR

............... das ist der Schlüssel Bei EVAX dürfte der Hauptteil der Party gelaufen sein. Obwohl man weiss ja nie, wieviele Anleger gestern nachbörslich Short gegangen sind. Wenn die auch noch gesqueezt werden, dann wird es nochmal lustig. Schaut euch mal das Setup bei GLTO oder SPRB an, Ausgangslage dort ähnlich explosiv, Freefloat ebenfalls sehr niedrig.

............... hohe Umsätze

gestern 10 % Minus, was ist passiert ?

............ schade, dass hier offenbar keiner mitdiskutieren möchte https://de.marketscreener.com/kurs/aktie/EVAXION-BIOTECH-A-S-118683095/news-historie/ Evaxion Biotech initiated with a Buy, $23 target at Ladenburg Ladenburg analyst Wangzhi Li initiated coverage of Evaxion Biotech with a Buy rating and $23 price target. Evaxion has built a "top-performing" neoAgs platform and pipeline that may potentially help address some of the current gaps for neoAgs vaccine, with "highly competitive" early clinical results shown, Li tells investors in a research note. The analyst sees the upcoming Phase 1/2 trial readouts in the first half of 2021 for Evaxion's two lead neoAgs vaccine programs as "potential significant near-term catalysts." Evaxion Biotech initiated with an Outperform at Oppenheimer Oppenheimer analyst Kevin DeGeeter initiated coverage of Evaxion Biotech with an Outperform rating and $18 price target. DeGeeter expects that Evaxion, a February 2021 IPO, will report important data from EVX-01 and EVX-02 in 2Q21 including durability of response for low-dose EVX-01, T-cell data for high-dose EVX-01 and immunogenicity data for EVX-02, which may serve as an inflection point for shares and offer opportunity for further balance sheet expansion, the analyst tells investors in a research note.